Clearline Capital LP Has $498,000 Stock Position in LENSAR, Inc. (NASDAQ:LNSR)

Clearline Capital LP trimmed its stake in LENSAR, Inc. (NASDAQ:LNSR - Free Report) by 67.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,652 shares of the company's stock after selling 117,352 shares during the period. Clearline Capital LP owned 0.48% of LENSAR worth $498,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in shares of LENSAR by 3.5% in the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company's stock valued at $460,000 after purchasing an additional 3,423 shares during the last quarter. Atria Investments Inc increased its position in LENSAR by 28.2% in the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company's stock worth $233,000 after buying an additional 5,729 shares during the period. Brandes Investment Partners LP lifted its holdings in shares of LENSAR by 10.4% during the fourth quarter. Brandes Investment Partners LP now owns 489,318 shares of the company's stock worth $4,375,000 after buying an additional 45,920 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of LENSAR by 13.3% in the fourth quarter. Renaissance Technologies LLC now owns 348,891 shares of the company's stock worth $3,119,000 after acquiring an additional 40,946 shares during the last quarter. Finally, Essex Investment Management Co. LLC raised its stake in LENSAR by 18.3% during the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company's stock valued at $357,000 after purchasing an additional 6,184 shares during the last quarter. 40.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LNSR has been the topic of a number of research reports. BTIG Research cut LENSAR from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 24th. Lake Street Capital reissued a "hold" rating and issued a $15.00 target price (down previously from $16.00) on shares of LENSAR in a research note on Monday, March 24th.

LENSAR Price Performance

Shares of LNSR stock traded up $0.03 during trading hours on Monday, reaching $13.95. 81,627 shares of the company were exchanged, compared to its average volume of 74,876. The company has a market cap of $164.50 million, a price-to-earnings ratio of -9.55 and a beta of 0.56. The stock's fifty day moving average is $14.15 and its two-hundred day moving average is $10.51. LENSAR, Inc. has a fifty-two week low of $3.50 and a fifty-two week high of $17.31.

LENSAR (NASDAQ:LNSR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($2.32) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($2.16). The business had revenue of $11.53 million for the quarter, compared to analyst estimates of $13.40 million. LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%.

LENSAR Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.